Efficacy and safety of Y-3 intracalvariosseous injection versus intravenous injection in the treatment of acute large hemispheric infarction (SOLUTION-2): rationale and design of a multicentre, prospective, randomised, open-label, blind endpoint (PROBE) trial

Efficacy and safety of Y-3 intracalvariosseous injection versus intravenous injection in the treatment of acute large hemispheric infarction (SOLUTION-2): rationale and design of a multicentre, prospective, randomised, open-label, blind endpoint (PROBE) trial

Rationale The blood–brain barrier (BBB) largely restricts the efficacy of neuroprotectants, which is an important approach in treating large hemispheric infarction (LHI). In this study, we harnessed intracalvariosseous (ICO) injection to bypass the BBB and facilitate drug delivery.Aim To compare the...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongjun Wang, Yilong Wang, Yuesong Pan, Mo Yang, Xuan Wang, Mengyuan Zhou, Weiming Liu, Zhiwei Sun, Meiyang Zhang, Nanxing Wang, Wenqian Liu, Yunwei Ou
Format: Article
Language:English
Published: BMJ Publishing Group
Series:Stroke and Vascular Neurology
Online Access:https://svn.bmj.com/content/early/2025/06/02/svn-2024-004011.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale The blood–brain barrier (BBB) largely restricts the efficacy of neuroprotectants, which is an important approach in treating large hemispheric infarction (LHI). In this study, we harnessed intracalvariosseous (ICO) injection to bypass the BBB and facilitate drug delivery.Aim To compare the efficacy and safety of ICO injection versus intravenous injection in the treatment of acute LHI within 24 hours of disease onset.Methods and design The efficacy and safety of Y-3 ICO injection versus intravenous injection in the treatment of acute LHI (SOLUTION-2) is a multicentre, prospective, randomised, open-label, blind endpoint trial. 134 patients with acute LHI from more than six centres will be enrolled and randomised in the trial to receive ICO or intravenous injection of Y-3 in a 1:1 ratio.Study outcomes The primary efficacy outcome is the proportion of patients with a modified Rankin Scale score of 0–3 at 90 days after symptom onset. Primary safety outcomes include infection events related to ICO injection procedures.Discussion Results from the SOLUTION-2 trial will contribute to the understanding of the efficacy and safety of the Y-3 ICO injection in patients with LHI.Trial registry The efficacy and safety of Y-3 ICO injection versus intravenous injection in the treatment of acute LHI (SOLUTION-2).URL https://clinicaltrials.gov/study/NCT06374667?cond=SOLUTION-2&intr=y-3&rank=1.Trial registration number NCT06374667.
ISSN:2059-8696

Similar Items